Rudimentary signs of immunosenescence in <em>Cytomegalovirus</em>-seropositive healthy young adults by Turner, James E et al.
        
Citation for published version:
Turner, JE, Campbell, JP, Edwards, KM, Howarth, LJ, Pawelec, G, Aldred, S, Moss, P, Drayson, MT, Burns, VE
& Bosch, JA 2014, 'Rudimentary signs of immunosenescence in Cytomegalovirus-seropositive healthy young
adults', Age, vol. 36, no. 1, pp. 287-297. https://doi.org/10.1007/s11357-013-9557-4
DOI:
10.1007/s11357-013-9557-4
Publication date:
2014
Document Version
Peer reviewed version
Link to publication
Original article available: http://www.springer.com/life+sciences/cell+biology/journal/11357
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019
1 
 
DOI 10.1007/s11357-013-9557-4 1 
Original article available: http://www.springer.com/life+sciences/cell+biology/journal/11357 2 
Rudimentary signs of immunosenescence in Cytomegalovirus seropositive healthy young 3 
adults  4 
 5 
JAMES E. TURNER*, 1, 2, 3, JOHN P. CAMPBELL 1, 4, KATE M. EDWARDS 5, LAUREN J. 6 
HOWARTH 1, GRAHAM PAWELEC 6, SARAH ALDRED 1, PAUL MOSS 2, MARK T. 7 
DRAYSON 4, VICTORIA E. BURNS 1, JOS A. BOSCH 7, 8 8 
 9 
1 School of Sport and Exercise Sciences, University of Birmingham, UK. 10 
2 School of Cancer Sciences, University of Birmingham, UK. 11 
3 Department for Health, University of Bath, UK. 12 
4 School of Immunity and Infection, University of Birmingham, UK. 13 
5 Exercise Health and Performance Research Group, University of Sydney,   Lidcombe, Australia 14 
6 Department of Internal Medicine II, Centre for Medical Research, University of Tübingen, 15 
Tübingen, Germany. 16 
7 School of Psychology, University of Amdterdam, Amsterdam, The Netherlands. 17 
8Mannheim Institute of Public Health, Social and Preventive Medicine (MIPH), Mannheim 18 
Medical Faculty, University of Heidelberg, Germany. 19 
 20 
*Correspondence: James E Turner. Address: Department for Health, University of Bath, BA2 21 
7AY, E-mail: j.e.turner@bham.ac.uk or turnerje1984@gmail.com (James E. Turner) or 22 
j.a.bosh@uva.nl (Jos. A. Bosch) 23 
 24 
2 
 
Running head: Immunosenescence in early adulthood 25 
Key words: Immunosenescence, Cytomegalovirus, Interleukin-6, CD8+ T cells, vaccination 26 
efficacy.27 
3 
 
Abstract 28 
 Ageing is associated with a decline in immune competence termed immunosenescence. 29 
In the elderly, this process results in an accumulation of differentiated ‘effector’ phenotype 30 
memory T cells, predominantly driven by Cytomegalovirus (CMV) infection. Here, we asked 31 
whether CMV also drives immunity towards a senescent profile in healthy young adults. 32 
 One hundred and fifty eight individuals (mean ± SD; age 21 years ± 3, body mass index 33 
22.7 kg·m2 ± 2.7) were assessed for CMV-serostatus, the numbers/proportions of CD4+ and 34 
CD8+ late-differentiated/effector-memory cells (i.e., CD27−CD28−/CD45RA+), plasma 35 
interleukin-6 (IL-6), and antibody responses to an in vivo antigen challenge (half-dose influenza 36 
vaccine). Thirty per-cent (48/158) of participants were CMV+. A higher lymphocyte and CD8+ 37 
count (both p<.01), and a lower CD4:CD8 ratio (p<.03) was observed in CMV+ people. Eight 38 
per-cent (4/58) of CMV+ individuals exhibited a CD4:CD8 ratio <1.0, whereas no CMV− donor 39 
showed an inverted ratio (p<.001). The numbers of CD4+ and CD8+CD27−CD28−/CD45RA+ 40 
cells were ~4-fold higher in CMV+ people (p<.001). Plasma IL-6 was higher in CMV+ donors 41 
(p<.05) and showed a positive association with the numbers of CD8+CD28− cells (p<.03). 42 
Finally, there was a significant negative correlation between vaccine-induced antibody responses 43 
to the A/Brisbane influenza strain and CMV-specific Immunoglobulin-G titres (p<.05). This 44 
reduced vaccination response was associated with greater numbers of total CD8+, and CD4+ and 45 
CD8+CD27−CD28−/CD45RA+ cells (p<.05). 46 
This study observed marked changes in the immune profile of young adults infected with 47 
CMV, suggesting that this virus may underlie rudimentary aspects of immunosenescence even in 48 
a chronologically young population.49 
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Introduction  50 
Ageing is associated with a gradual decline in immune competence, termed 51 
immunosenescence, which has been associated with increased susceptibility to infection, 52 
accelerated cognitive decline, frailty, and increased mortality (Wikby et al. 2005). A hallmark of 53 
immunosenescence is an accumulation of differentiated or ‘effector’ phenotype CD8+ T cells 54 
(i.e., CD27−CD28−/CD45RA+). Other characteristics include a decline in the frequency and 55 
number of naïve CD8+ T cells (i.e., CD27+CD28+/CD45RA+) and increased inflammatory 56 
activity (e.g., plasma IL-6 levels) (Chidrawar et al. 2009; Wikby et al. 2005; Derhovanessian et 57 
al. 2009). It has become clear that these features are to a significant extent determined by latent 58 
Cytomegalovirus (CMV) infection (Derhovanessian et al. 2009; Olsson et al. 2000). CMV is a 59 
beta-herpes virus that establishes lifelong latency after primary infection. Seroprevalence, as 60 
determined by the presence of CMV-specific Immunoglobulin-G antibodies (anti-CMV IgG), 61 
increases with age to reach levels of over 70% in many elderly populations (Staras et al. 2006).  62 
It has been shown that the magnitude of the CMV-specific immune response can also 63 
influence clinical outcomes in CMV seropositive individuals. High titres of anti-CMV IgG and 64 
increased numbers of late-differentiated CD8+ T cells (i.e., CD27−CD28−) have been associated 65 
with lower antibody responses to influenza vaccination and higher circulating levels of 66 
inflammatory markers (Saurwein-Teissl et al. 2002; Goronzy et al. 2001; Trzonkowski et al. 67 
2003; Wikby et al. 2006; Moro-Garcia et al. 2012). In contrast, a recent study observed 68 
comparable antibody responses to influenza vaccination, irrespective of CMV serostatus, in 69 
residents of long-term care facilities (den Elzen et al. 2011). Indeed, as with the latter study, most 70 
observations of this kind have been made in elderly individuals that might already exhibit 71 
immune impairment. Thus, it remains largely unexplored whether CMV infection also drives 72 
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immunity towards a senescent immune profile in healthy young adults. Here, in a 73 
chronologically young population, we have examined the influence of CMV serostatus on 74 
immune parameters including the CD4:CD8 ratio, the number of late-differentiated/effector 75 
memory T cells and plasma IL-6 levels, as well as the in vivo functional response to antigen 76 
challenge (a half dose influenza vaccine). 77 
 78 
 79 
80 
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Methods 81 
Participants 82 
 One hundred and fifty eight healthy university students were recruited by local campus 83 
advertisement (Edwards et al. 2010). Mean ± SD age and body mass index (BMI) were 21 years 84 
± 3, and 22.7 kg·m2 ± 2.7, respectively. An equal number of males and females were recruited, 85 
and 90% were of White-British ethnicity. Exclusion criteria were smoking and self reported 86 
history of inflammatory, autoimmune or cardiovascular disease, self-reported pregnancy or 87 
suspected pregnancy, and use of prescription medication in the past month (excluding the 88 
contraceptive pill). Participants self-reported no influenza-like illness in the year preceding this 89 
investigation, and no symptoms of acute infection at the time of vaccination and follow up 90 
measurements. All participants provided written informed consent and the study protocol was 91 
approved by the Black Country Local Research Ethics Committee.  92 
 93 
Procedures 94 
 Participants visited the laboratory between 12:00 and 16:00 to provide a baseline pre-95 
vaccine blood sample and to receive an influenza vaccination. Participants returned to provide 96 
additional blood samples 24-h and 28-d after vaccination. Before arrival, participants were 97 
instructed to abstain from vigorous exercise and over-the-counter medication for 24-h, alcohol 98 
for 12-h, and food or caffeine for 2-h prior to their visit. Immediately after the baseline blood 99 
sample, and prior to vaccination, the majority of participants (n = 119) undertook a 25-min 100 
exercise intervention involving a series of weight lifting exercises. The results of this 101 
manipulation are described elsewhere (Edwards et al. 2010) and did not influence the present 102 
results.  103 
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 104 
Vaccination 105 
  Influenza vaccination was used as a marker of in vivo immune function (Burns and 106 
Gallagher 2010). To increase sensitivity of this marker, a half-dose (0.25ml / 7.5µg; 50% adult 107 
recommended dose) of the 2008/2009 northern hemisphere influenza vaccine (Fluarix, 108 
GlasxoSmithKline, Inactivated Split Virion, Lot No. AFLUA384AB) was used. The vaccine 109 
contained A/Brisbane- (both H3N2 and H1N1 strains), A/Uruguay- (H1N1 strain), and 110 
B/Florida-like strains. A nurse administered the vaccine via intra-muscular injection into the 111 
deltoid.  112 
 113 
Blood sample processing  114 
 Serum was obtained by allowing blood to clot in plain Vacutainer tubes (Becton-115 
Dickinson, UK), centrifuging at 3400 g for 5 min at 21 °C, and was stored at −20 °C. Plasma was 116 
obtained by centrifuging blood in potassium ethylene-diamine-tetra-acetic acid (K3EDTA) 117 
Vacutainer tubes at 3400 g for 10 min at 1 °C, and was stored at −80 °C.  118 
 119 
Assays 120 
 Influenza antibody titre was determined in serum before vaccination (baseline) and at 28-121 
d using a haemagglutination inhibition test as previously described (Edwards et al. 2010). An 122 
antibody titre represents the highest serum dilution to inhibit the agglutination of test 123 
erythrocytes which bind together into a lattice-like structure upon exposure to influenza virus 124 
particles (Burns and Gallagher 2010). Anti-CMV IgG and IL-6 were measured in plasma before 125 
vaccination (baseline). CMV-seropositivity was defined as having an anti-CMV IgG titre > 3 126 
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IU/ml by ELISA, according to manufacturer instructions (Genesis Diagnostics, UK). IL-6 was 127 
measured using a high sensitivity ELISA (Quantikine HS Human IL-6 ELISA, R&D Systems, 128 
UK). Assay sensitivity was 0.1 IU/ml and 0.039 pg/ml for the CMV and IL-6 ELISAs 129 
respectively. Only one individual fell below the sensitivity threshold for IL-6 (0.02 pg/ml) and 130 
was included in analyses. Intra- and inter-assay precision (CV %) were <10% for both assays.  131 
 132 
Flow cytometry and immunophenotyping  133 
Leukocyte differential was assessed in K3EDTA blood 24-h post-vaccination and 134 
repeated 28-d later (Coulter ACTdiff haematology analyser; Beckman-Coulter, High Wycombe, 135 
UK). These samples were processed for flow cytometric measurements as previously described 136 
(Turner et al. 2010). Fixed cell preparations were read on a multi-parameter flow cytometer (BD 137 
FACS CANTO II, BD Biosciences). Lymphocytes were gated on the forward versus side-scatter. 138 
Sub-populations of CD3+CD4+and CD3+CD8+ T cells were identified using two analytical 139 
strategies. First, expression of CD27 in combination with CD45RA identified naïve 140 
(CD27+CD45RA+), central memory (CD27+CD45RA−; CM), effector memory 141 
(CD27−CD45RA−; EM), ‘revertant’ effector memory cells which re-express CD45RA 142 
(CD27−CD45RA+; EMRA). Second, CD27 expression was analysed in combination with CD28 143 
to identify early- (CD27+CD28+), intermediate- (CD27+CD28−) and late-differentiated 144 
(CD27−CD28−) sub-populations (Hamann et al. 1997; Appay et al. 2002). Data were analysed 145 
with FlowJo (Treestar, Ashland, OR). 146 
 147 
Statistical analyses 148 
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 Data were inspected for normal distribution using the Kolmogrov-Smirnov test. Non-149 
normally distributed data were transformed logarithmically. Differences between CMV+ and 150 
CMV− participants were assessed with univariate analyses of variance (ANOVA) (continuous 151 
variables) or Chi-squared tests (categorical variables). Relationships between IL-6 and 152 
lymphocyte sub-populations were established using stepwise regression analysis. Anti-influenza 153 
antibody titres were assessed between baseline and 28-d post-vaccination with repeated measures 154 
ANOVA. To identify factors moderating the vaccination response, key variables (e.g., anti-CMV 155 
IgG) were entered into ANOVAs as individual covariates and examined for significance 156 
(Analysis of co-variance; ANCOVA). Significant covariates were further examined adjusting for 157 
sex, CMV serostatus, baseline influenza antibody titre, and the pre-vaccine exercise-intervention. 158 
Pearson’s correlations established the direction of relationships between key variables (e.g., anti-159 
CMV IgG) and fold change of influenza antibody titre. Fold change was calculated by dividing 160 
the geometric mean antibody titre by the baseline titre. Effect sizes are reported as eta-squared 161 
(η2). Conventionally, η2 values of 0.01, 0.06, and 0.14 are considered small, medium and large 162 
effect sizes respectively. For example, η2 of 0.25 indicates that 25% of the observed effects (i.e., 163 
dependent variable) are accounted for by the experimental manipulation (i.e., the independent 164 
variable). Data are presented as means ± standard error of the mean (SEM) unless otherwise 165 
stated. Data were analysed using SPSS statistical package version 18.0 for Windows (SPSS Inc., 166 
USA). 167 
168 
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Results 169 
 170 
CMV serostatus  171 
 Approximately 30% of individuals (n = 48/158) were CMV+ as determined by anti-CMV 172 
IgG titres > 3 IU/ml. CMV-serostatus was not associated with age, sex, ethnicity or BMI (p > 173 
.1).  174 
 175 
CMV seropositivity is associated with a higher lymphocyte count and lower CD4:CD8 ratio 176 
 Lymphocyte and T cell sub-population data was averaged for the two collection days 177 
(i.e., 24-h and 28-d post-vaccination). Analyses showed that for both days, the proportions of 178 
cells were identical (p > .38), except for CD8+CD27− CD45RA−/+ cells (p < .01) and correlated 179 
between samples (average correlation r = .72, p < .001). Moreover, results reported below 180 
remained the same when collection days were analysed separately.  181 
 CMV-seropositivity was associated with a higher lymphocyte count and a greater number 182 
of CD8+ T cells (F (1, 152) > 8.1; p < .01, η2 > .050; data not shown). CMV-seropositivity was also 183 
associated with a significantly lower CD4:CD8 ratio (F (1, 152) = 5.1, p < .03, η2 = .032; see Figure 184 
1A). It is notable that a CD4:CD8 ratio < 1.0 was observed in 4/48 CMV+ individuals (8% of 185 
CMV+) and none of the CMV− individuals (independent samples t-test; t (108) 3.8, p < .001).  186 
 187 
CMV infection is associated with an expansion of late-differentiated effector memory CD4+ and 188 
CD8+T cells  189 
  The numbers and proportions of CD4+ and CD8+ EM (CD27−CD45RA−), EMRA 190 
(CD27−CD45RA+), and late-differentiated (CD27−CD28−) cells were significantly increased in 191 
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CMV+ individuals (F (1, 152) > 30.6; p < .001, η2 > .167, see Figure 1B, 1C and Table I). Further, 192 
individuals with higher anti-CMV IgG titres (in CMV+ participants) had increased numbers of 193 
total lymphocytes, CD8+ EMRA, and CD4+ late-stage differentiated cells (Pearson’s correlations 194 
r = .32 to .38, p < .03; CD8+ late-differentiated cells r = .27, p = .064; see Figure 2 A-D).  195 
 196 
Plasma IL-6 is increased with CMV infection and associated with the number of CD8+ CD28− 197 
cells 198 
 Modestly elevated plasma IL-6 was observed in CMV+ individuals, as compared to 199 
CMV− donors (F (1, 152) = 4.3, p < .05, η2 = .027; see Figure 3A). Individuals with higher IL-6 had 200 
increased numbers of both intermediate (CD27+CD28−) and late-stage (CD27−CD28−) 201 
differentiated CD8+ cells (Pearson’s correlation r > .18, p < .03; data not shown). The 202 
relationship between CD28− cells and IL-6 was largely an effect of CMV infection. After 203 
statistical adjustment for anti-CMV IgG, the association between IL-6 and late-stage 204 
differentiated (CD27−CD28−) cells was lost. This association remained close to significance for 205 
intermediate-stage (CD27+CD28−) cells (r = .19; p < .05). 206 
 207 
Higher anti-CMV IgG titres are associated with weaker antibody responses to A/Brisbane 208 
antigen 209 
 CMV serostatus did not predict vaccination responses (defined as a > 4 fold change in 210 
antibody titre 28-d post-vaccination) to any of the influenza strains (p > .1). However, a higher 211 
concentration of anti-CMV IgG was associated with a smaller increase in antibody titres against 212 
the A/Brisbane antigen (anti-CMV IgG × time interaction F (1, 152) = 4.1, p < .05, η2 = .026; 213 
Pearson’s correlation r =.16 p < .05; see Figure 3B). This effect remained significant after 214 
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statistical adjustment for sex, A/Brisbane baseline antibody titre, and the pre-vaccine exercise 215 
intervention (Adjusted anti-CMV IgG × time interactions; F (1, 155) > 3.9, p < .05, η2 > .025). 216 
There were no relationships between anti-CMV IgG and antibody responses to the other 217 
influenza strains. 218 
 219 
High numbers of total lymphocytes and late differentiated T cells are associated with smaller 220 
antibody responses to A/Brisbane antigen 221 
  A weaker A/Brisbane antibody response was associated with a higher total lymphocyte 222 
and CD8+ T cell count, as well as increased numbers of late-differentiated CD4+ and CD8+ T 223 
cells (CD27−CD28−), and CD8+ EM (CD27−CD45RA−) and EMRA (CD27−CD45RA+) cells 224 
(cell population × time interactions F (1, 156) > 4.4, p < .05, η2 > .041; Pearson’s correlations r = 225 
−.16 to −.23, p < .05). These effects remained significant after statistical adjustment for sex, 226 
A/Brisbane baseline antibody titre, and the pre-vaccine exercise intervention (Adjusted analyses 227 
all; F (1, 155) > 4.2, p < .05, η2 > .019). However, the observation that individuals with higher cell 228 
counts exhibited smaller A/Brisbane antibody responses was largely an effect of CMV infection. 229 
After statistical adjustment for anti-CMV IgG or CMV serostatus, most of these associations 230 
were lost, except for total lymphocytes and total CD8+ T cells (Analyses adjusted for CMV 231 
infection; F (1, 155) > 4.2, p < .05, η2 > .026). There were no relationships between lymphocyte and 232 
lymphocyte sub-populations with antibody responses to the other influenza strains. 233 
234 
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Discussion  235 
 The results of this study show that young adults infected with CMV exhibit mild signs of 236 
immunosenescence, characterised by increased numbers of late-differentiated/effector memory T 237 
cells and elevated inflammatory activity. The present study adds to the very sparse data on the 238 
relationship between CMV and T cell differentiation in healthy young adults, and is the first to 239 
confirm that the magnitude of the humoral response to CMV (i.e., anti-CMV IgG) is associated 240 
with an accumulation of late-differentiated/effector memory T cells. Until now, to the best of our 241 
knowledge, this phenomenon has only been shown in elderly subjects (Alonso Arias et al. 2013; 242 
Vescovini et al. 2010). Moreover, donors with the strongest CMV-specific immune response, 243 
characterised by high anti-CMV IgG titres and memory T cell numbers, exhibited a reduced 244 
antibody response to a half-dose influenza vaccination. 245 
Although the majority of individuals exhibited a > 4 fold change in antibody titre 28 days 246 
post-vaccination to each influenza strain (i.e., individuals were World-Health-Organisation 247 
defined “vaccine responders”), we found that an increased anti-CMV IgG titre was associated 248 
with a smaller antibody response to the A/Brisbane influenza antigen only. Anti-CMV IgG was 249 
also associated with increased numbers of late-differentiated/effector memory T cells. In turn, a 250 
higher number of these cells also associated with lower vaccine responses to the A/Brisbane 251 
antigen, but this was a consequence of CMV infection: when controlling statistically for CMV 252 
serostatus, or anti-CMV IgG titre, most of these associations were lost.  253 
It is unclear why our observations were limited to the A/Brisbane vaccine component, 254 
although strain-specific differences in the magnitude of antibody response to influenza 255 
vaccination have commonly been reported in a variety of contexts. For example, obese 256 
individuals have been shown to exhibit larger antibody responses to single influenza vaccine 257 
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components (Sheridan et al. 2012; Talbot et al. 2012). Further, sexual dimorphism and diurnal 258 
variation in vaccine efficacy has been observed with single influenza sub-types in trivalent 259 
vaccines (Phillips et al. 2008; Langlois et al. 1995). Finally, the age-associated decline in 260 
antibody response to vaccination is not uniform between strains. Differences in antibody 261 
response between young and old are largest with H1N1 and B antigens, compared to H3N2 262 
antigens (Goodwin et al. 2006). Indeed, our laboratory has repeatedly shown that weaker vaccine 263 
antigens are the most sensitive to mild forms of immunomodulation, such as exercise or chronic 264 
stress (Edwards et al. 2006; Edwards et al. 2007; Edwards et al. 2010; Edwards et al. 2008; 265 
Burns and Gallagher 2010). We speculate that strain-specific variation in the immunogenicity of 266 
vaccine components might explain contradictory findings in the literature (Burns and Gallagher 267 
2010; Burns et al. 2003; den Elzen et al. 2011; Goodwin et al. 2006). In the present study, the 268 
A/Brisbane strain was the most immunogenic vaccine component (Edwards et al. 2010) 269 
consisting of both H1N1 and H3N2 subtypes, which show greatest age-related differences in 270 
immunogenicity (Goodwin et al. 2006). Significantly, H3N2 was highly prevalent around the 271 
time of this investigation (CDC 2008) and is the strain associated with most influenza-related 272 
complications and deaths (Thompson et al. 2003). It is therefore fascinating to show that the 273 
immunosuppressive effects of CMV infection can be observed with highly immunogenic 274 
influenza vaccine components in such a young and healthy population. Thus, the present findings 275 
provide further support for the concept that CMV is a major driving force behind 276 
immunosenescence and might result in vaccine failure and increased infection risk in CMV 277 
seropositive individuals (Derhovanessian et al. 2009).  278 
It is currently unknown exactly how infection with CMV could promote lower antibody 279 
responses to vaccination. Immunosenescence and chronological ageing might be associated with 280 
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impaired dendritic cell function (Panda et al. 2010). It is unclear whether this is a direct effect of 281 
CMV infection on antigen presenting cells, or a secondary downstream consequence of infection 282 
(e.g., indirect effects caused by the accumulation of memory T cells). Indeed, dendritic cell 283 
function is impaired by co-incubation with CD8+CD28− cells, which promote expression of 284 
negative regulatory receptors such as immunoglobulin-like transcripts 3 and 4 (ILT3 and ILT4) 285 
(Chang et al. 2002). In addition, CD8+CD28− cells cause a down-regulation of CD40-ligand on 286 
CD4+ T helper cells (Cortesini et al. 2001) and the ensuing impaired responsiveness of CD4+ T-287 
helper cells may in turn inhibit antibody production, which is a hallmark of B cell 288 
immunosenescence (Siegrist and Aspinall 2009). 289 
It is notable that 8% of CMV+ individuals (4/58) in the present study showed an inverted 290 
CD4:CD8 ratio of less than 1.0. This marker of immunosenescence is a hallmark of the ‘Immune 291 
Risk Profile’ (IRP), an immune phenotype observed in around 15% of people aged over 85 years 292 
in the Swedish OCTO/NONA studies. The IRP is a cluster of immunological markers, including 293 
the accumulation of CD8+ memory T cells (resulting in an inverted CD4:CD8 ratio) as well as 294 
CMV infection, which predicts all cause mortality in the very old (Wikby et al. 2006; 295 
Derhovanessian et al. 2009; Wikby et al. 2005). Further, a recent 10-year follow up of ~14,000 296 
adults from the National Health and Nutrition Examination Survey (NHANES) provides 297 
evidence that CMV infection alone predicts all cause mortality independently of inflammatory 298 
activity (CRP level) (Simanek et al. 2011). The results of the present study suggest that a mild 299 
IRP-like phenotype (which might be associated with mortality) can be observed in some adults 300 
much earlier in life than has been reported previously. 301 
 To the best of our knowledge, we have shown for the first time that healthy young adults 302 
latently infected with CMV exhibit increased levels of IL-6. Until now, interaction between IL-6 303 
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and pathogen burden has only been observed in the elderly (Nazmi et al. 2010; Schmaltz et al. 304 
2005). This result seems mechanistically plausible considering the strong in vitro evidence that 305 
CMV infection in a variety of cell types, including monocytes, epithelial cells, and adipocytes, 306 
results in a marked increase of IL-6 gene and protein expression (Bouwman et al. 2009; Geist 307 
and Dai 1996; Iwamoto and Konicek 1997; Visseren et al. 1999). Increased IL-6 is thought to 308 
reflect viral reactivation (Bennett et al. 2011) due to a potential role for this cytokine in chronic 309 
viral control (Harker et al. 2011). The present manuscript also shows that elevated IL-6 level is 310 
associated with the numbers of CD8+ CD28− T cells. Although our data suggest this relationship 311 
is largely a direct effect of CMV infection, a causal relationship between CD8+ CD28− T cells 312 
and IL-6 is biologically plausible. For example, CD8+CD28− are efficient producers of 313 
inflammatory cytokines such as TNF-α, IFN-γ and IL-6 (Zanni et al. 2003; Lorre et al. 1994; 314 
Effros et al. 2005). In addition, an association between systemic inflammation and an 315 
accumulation of CD8+CD28− cells has also been found in healthy older adults (Zanni et al. 2003; 316 
Wikby et al. 2006), as well as in a variety of auto-immune diseases including rheumatoid 317 
arthritis, multiple-sclerosis and Graves’ disease (Sun et al. 2008; Schmidt et al. 1996; Markovic-318 
Plese et al. 2001). Together, our results extend the existing literature that links the concept of 319 
‘inflamm-ageing’ and T cell senescence (Franceschi et al. 2000) by showing that such 320 
associations may even be present in healthy young adults, likely driven by CMV infection. 321 
 In the present study, individuals infected with CMV exhibited plasma IL-6 levels 322 
approximately 20% higher than CMV-negative individuals. This is comparable to the elevated 323 
level of IL-6 seen with men and women who develop coronary heart disease later in life, 324 
compared to those who remain healthy (Pai et al. 2004). The present finding may thus provide an 325 
additional mechanism by which CMV has been implicated in the development of cardiovascular 326 
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disease (Soderberg-Naucler 2006; Strandberg et al. 2009). Individuals with a Guanine > Cytosine 327 
single-nucleotide-polymorphism (SNP) at position −174 in the promoter region for the IL-6 gene 328 
show ~60% increase in IL-6 levels, and are at greater risk of cardiovascular disease (Rafiq et al. 329 
2007). It would be interesting to examine whether being CMV seropositive with this SNP carries 330 
a further increased risk of disease (Soderberg-Naucler 2006; Pai et al. 2004).  331 
This study does not provide data on specific T cell responses to CMV infection (e.g., 332 
IFN-γ production to CMV antigens and MHC-class I or II tetramer staining). However, in CMV-333 
seropositive individuals, it is well accepted that the majority of CD27− and CD28− T cells are 334 
CMV-specific. Moreover, a substantial number of studies have shown positive correlations 335 
between the number of late-differentiated/effector-memory T cells and the CMV-specific 336 
immune response across a range of ages (Griffiths et al. 2013; Lachmann et al. 2012; Khan et al. 337 
2002; Pita-Lopez et al. 2009). In future studies, such measurements of CMV-specific T cells 338 
could be correlated with the antibody response to influenza vaccination in young adults. While 339 
this data may not necessarily contribute to our understanding of the mechanisms underlying 340 
diminished vaccine responses, it would broaden our understanding of CMV infection in young 341 
adults, and might provide a potential predictor of vaccine efficacy in CMV infected people. 342 
Based on the small amount of data on this topic, it might be expected that the magnitude of IFN-343 
γ production by CMV specific T cells in young adults would be negatively associated with 344 
influenza vaccine responses, as has been shown in the elderly (Moro-Garcia et al. 2012). 345 
 The role of CMV in immunosenescence remains a topic of debate (Wills et al 2011). For 346 
example, it has been shown that in residents of long-term care facilities, CMV does not impair 347 
the antibody response to influenza vaccination (den Elzen et al. 2011). In light of these and other 348 
inconsistent findings, it cannot be assumed that the effects of CMV shown in the elderly in some, 349 
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but not all studies, will translate into young adults. In the present study, by measuring multiple 350 
biomarkers of immunosenescence, we confirm that the deleterious effects of CMV infection, 351 
sometimes shown in the elderly, do indeed translate to young adults (Saurwein-Teissl et al. 2002; 352 
Goronzy et al. 2001; Trzonkowski et al. 2003; Wikby et al. 2006). Our findings show that 353 
healthy university students, infected with CMV, exhibit an accumulation of late-354 
differentiated/effector memory T cells, increased inflammatory activity, and poorer immune 355 
responses to novel antigens early in life (i.e., well before overt signs of immune impairment 356 
appear). It should be considered however, that the population examined in this work are a 357 
socially homogenous group of young adults, the majority of whom were of White-British 358 
ethnicity, and of high socio-economic status. Making identical measurements in a more 359 
heterogenous group of individuals might result in larger and stronger effects of CMV on the 360 
results presented. 361 
The present observations are relevant to influenza control and might also apply to other 362 
routine vaccination programmes (e.g., Hepatitis B). Likewise, these findings might warrant 363 
investigation of vaccine efficacy in other contexts, such as yellow fever, which is important 364 
considering the popularity of worldwide travel. Another implication is that the current findings 365 
suggest a different theoretical approach to T cell immunosenescence, which might be relevant to 366 
the type and timing of interventions that intend to ameliorate or prevent immunosenescence 367 
(Adler 2008; Pawelec et al. 2010). Traditional thinking is that senescence is primarily driven by 368 
thymic involution, whereby CMV infection could act as a secondary or amplifying, factor. The 369 
current observations instead suggest a more primary role of CMV in establishing rudimentary 370 
features of immunosensencence very early in life, whereby subsequent thymic involution may 371 
potentially act as a secondary feature.      372 
373 
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 559 
Table I. Proportion of lymphocyte subpopulations in CMV− and CMV+ participants (mean 560 
± SD) 561 
Cells % † CMV − CMV + 
CD4+ # 39.44 ± 6.18 38.53 ± 5.55 
CD4+ naïve 46.26 ± 10.27 44.81 ± 10.96 
CD4+ CM 48.61 ± 9.23 46.16 ± 9.54 
CD4+ EM 4.90 ± 2.31 7.50 ± 4.22*** 
CD4+ EMRA 0.22 ± 0.49 1.53 ± 3.83*** 
CD4+ early 93.60 ± 2.60 89.68 ± 7.32* 
CD4+ inter 1.27 ± 0.81 1.28 ± 1.03 
CD4+ late 0.19 ± 0.43 3.29 ± 6.07*** 
CD8+ # 20.77 ± 4.12 23.42 ± 5.36** 
CD8+ naïve 57.77 ± 10.52 48.69 ± 13.71*** 
CD8+ CM 34.38 ± 9.35 30.10 ± 11.97** 
CD8+ EM 3.88 ± 2.68 7.23 ± 5.48*** 
CD8+ EMRA 3.96 ± 5.32 13.98 ± 11.12*** 
CD8+ early 79.38 ± 9.14 65.98 ± 14.88*** 
CD8+ inter 12.78 ± 6.44 12.81 ± 8.18 
CD8+ late 5.39 ± 5.54 15.90 ± 12.87*** 
 562 
†Cells as a proportion of CD4+ or CD8+ T lymphocytes  563 
#Cells as a proportion of Lymphocytes  564 
*** p< .001, ** p< .01, * p< .05, Univariate ANOVA  565 
 566 
 567 
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 569 
Figure legends 570 
Figure 1. Composition of the T cell pool with CMV infection. A) Ratio of CD4+ to CD8+ T 571 
lymphocytes. 4/58 CMV+ individuals (8%) exhibited a ratio < 1.0. B) CD4+ and CD8+ effector 572 
memory (EM; CD27−CD45RA−) and ‘revertant’ effector memory (EMRA; CD27−CD45RA+) T 573 
lymphocytes. C) CD4+ and CD8+ T intermediate-stage (CD27+CD28−) and late-differentiated 574 
(CD27−CD28−) T lymphocytes. Data are means ± SEM. *** p < .001, * p < .05 CMV+ compared 575 
to CMV−. 576 
 577 
Figure 2. Significant* associations between anti-CMV IgG and lymphocyte populations. A) 578 
Total lymphocytes. B) CD8+ ‘revertant’ effector memory (EMRA; CD27−CD45RA+) T 579 
lymphocytes. C) CD4+ late-differentiated (CD27−CD28−) T lymphocytes. D) CD8+ late-580 
differentiated (CD27−CD28−) T lymphocytes (*p = .064). Statistical analyses were restricted to 581 
CMV+ individuals (n=48) and were conducted on log10 data. β represents standardised 582 
regression coefficient. 583 
 584 
Figure 3. Elevated inflammatory activity and reduced antibody responses to antigen challenge 585 
with CMV infection. A) Plasma IL-6 concentration. B) Data depicts association between anti-586 
CMV IgG titre and fold change in A/Brisbane antibody titre 28 d after influenza vaccination (p < 587 
.05). For illustrative purposes, anti-CMV IgG is presented in quartiles; CMV− < 3.0 IU/ml, 588 
CMV+ low 3.0-5.1 IU/ml, CMV+ med 5.1-9.1 IU/ml, CMV+ high > 9.1 IU/ml. Statistical 589 
analyses was conducted on continuous data (Altman and Royston 2006). Data are means ± SEM. 590 
*** p < .001, * p < .05 CMV+ compared to CMV−. 591 
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